Utility of Genomic Profiling Use for Targeted Therapy in a Phase I Setting Reveals that ESCAT I/II Actionable Targets are Associated with Improved Outcomes By Ogkologos - May 6, 2025 596 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CoPPO study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR FDA Approves Capivasertib with Fulvestrant for Breast Cancer November 23, 2023 Sotorasib Shows Increase in PFS and a More Favourable Safety Compared... February 21, 2023 A new approach to cancer immunotherapy March 18, 2022 Spending Review 2021: Promising commitments, but a lot of unanswered questions October 27, 2021 Load more HOT NEWS Program Helps Medically Underserved, Minority Cancer Survivors Be More Active Why the voices of people affected by cancer are critical to... ¿Qué son los biosimilares para el tratamiento del cáncer? Telephone-Based Rehab Program Helps People with Advanced Cancer Maintain Independence
